Newsroom :: CytoDyn Inc. (CYDY)

CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

Aug 12, 2024 8:30am EDT

Press Release

CytoDyn Announces Settlement with Amarex Clinical Research LLC

Jul 09, 2024 8:30am EDT

Press Release

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Jun 27, 2024 8:30am EDT

Press Release

CytoDyn to Host Webcast to Provide Company Update

May 28, 2024 8:30am EDT

Press Release

May 2024 Letter to Shareholders

May 16, 2024 8:30am EDT

Press Release

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 29, 2024 8:30am EST

Press Release

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Feb 01, 2024 8:30am EST

Press Release

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Jan 29, 2024 8:30am EST

Press Release

CytoDyn Announces Webcast to Provide Company Update

Dec 07, 2023 4:00pm EST

Press Release

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

Nov 21, 2023 8:30am EST

Press Release

1
2
3
4
5